Compass Minerals: Oversold, Undervalued and Offering a Tactical Long Entry

Hook & thesis

Compass Minerals (CMP) has been beaten down from its June highs near $34 to the low $20s even though the company still generates meaningful free cash flow and sits at an EV/EBITDA multiple that looks reasonable for a cyclical: 7.25x. With a market cap around $924M and enterprise value of roughly $1.62B, the market is assigning a low-growth, high-risk premium to the stock. That creates a tactical long opportunity for disciplined traders who can stomach operational volatility and the companys leverage.

My thesis: if near-term weather-related headwinds in the Salt segment and lingering accounting/legal noise remain contained and the Plant Nutrition business sustains demand, CMP can re-rate toward a low-double-digit EV/EBITDA multiple and offer 20%+ upside over a multi-month holding period. The trade is not a buy-and-forget: its a position trade with tight risk management and clear stop placement.

What Compass Minerals does and why it matters

Compass Minerals produces and markets salt, sulfate of potash (a specialty fertilizer), and magnesium chloride. The Salt segment supplies road deicing, dust control, food processing and industrial uses. The Plant Nutrition segment sells sulfate of potash to growers and distributors. The business is cyclical and exposed to weather (which drives deicing demand) and agricultural cycles (which affect fertilizer volumes and pricing).

Why the market should care: CMP combines defensive-like product demand (road salt) with higher-margin specialty fertilizers that can grow when crop economics improve. The company also carries significant fixed costs and leverage, so volatility in demand or input costs amplifies earnings swings - thats why the stock can fall sharply on tough weather or operational hiccups but rally quickly on evidence of demand normalization or margin recovery.

What the numbers say

Key fundamentals from the latest snapshot:

• Market cap: $923.99M; Enterprise value: $1.623B.
• EV/EBITDA: 7.25x - a cyclical multiple that implies recovery upside if EBITDA stabilizes.
• Free cash flow: $77.9M - positive and meaningful relative to market cap.
• Price to earnings: ~50.3x (EPS $0.44, price ~22.04) - reflects depressed trailing earnings and possibly recent losses in quarters.
• Price to sales: 0.72x - suggests revenue is modest relative to market cap.
• Debt-to-equity: 2.86 - leverage is high and central to the companys risk profile.
• 52-week range: $16.40 - $34.50; current price near $22 is closer to the low end.

Those figures create a mixed picture. On the plus side, EV/EBITDA below 8x and nearly $78M in free cash flow give us a quantitative basis for an upside re-rate. On the negative side, trailing EPS is low and the balance sheet is leveraged, which amplifies downside if business conditions deteriorate.

Recent operational context

• Compass has reported weather-related softness in the Salt segment and inventory-management challenges that pressured results in earlier quarters, producing an adjusted loss in Q1 2025 and operational volatility noted in subsequent updates.
• Plant Nutrition has shown revenue growth, helping offset some Salt weakness according to company commentary in prior updates.
• The company has been resolving accounting and governance matters: there are derivative suits that were proposed to be settled with corporate governance reforms and insurer-paid attorneys fees.

Valuation frame

The market cap of around $924M against an enterprise value of $1.62B and EV/EBITDA of 7.25x implies the market expects continued headwinds or structurally lower earnings. If CMP can sustain mid-cycle EBITDA closer to levels implied by recent free cash flow (remember FCF of $77.9M), a move to 9-10x EV/EBITDA would imply meaningful upside from here. Conversely, if weather, pricing or input-costs drive another weak season and debt costs stay high, multiples could compress further.

Without direct peers provided in this note, think of this as a capital-intensive specialty-chemicals / specialty-agribusiness business where single-digit EV/EBITDA multiples are common when markets expect cyclical low points. The current multiple is below 10x, which to me looks like a tactical entry band if the technicals and near-term news flow cooperate.

Technical backdrop

• Price is trading well below the 10/20/50-day SMAs (SMA-10: $23.02, SMA-20: $23.97, SMA-50: $25.82) and the 9/21/50-day EMAs - the short-term technicals are bearish.
• RSI sits around 27.4 - oversold territory suggesting a technical bounce is plausible.
• Short interest has risen over recent months with ~2.07M shares short as of 9/15/2026 and a days-to-cover around 5.3 - a potential squeeze can occur if sentiment shifts, but high short interest also signals bearish sentiment.

Trade plan (actionable)

Positioning: Tactical long with strict risk controls.

• Entry: $22.01 (market or limit execution). This is the current price area and offers a measurable reference point.
• Stop loss: $19.00. If price breaks back below $19 it suggests the downtrend is extending and downside to the mid-teens is more likely.
• Primary target: $28.00. This reflects a re-rating toward a more normalized EV/EBITDA multiple and partial realization of recovery in Salt and Plant Nutrition.
• Alternate target / stretch: $34.50 (52-week high) for traders who want to trail the stop into stronger momentum.
• Size: Use a position size that limits portfolio risk to a predetermined percent if stop is hit given $3.01 downside from entry to stop.

Horizon: position trade - mid term (45 trading days). Rationale: re-rating and operational improvements that change sentiment usually take several weeks to a few months to materialize. The 45-trading-day window lets you ride an earnings or operational update-driven move without committing to long-term capital while avoiding intraday noise. If the setup strengthens, the trade can be extended to long_term (180 trading days) with a raised stop and phased profit-taking.

Catalysts that could push this trade in our favor

• Improved winter weather demand or better-than-expected road salt sales in upcoming reporting seasons.
• Sustained growth in the Plant Nutrition business and better pricing/volume mix for sulfate of potash.
• Clear progress on corporate governance/accounting items that reduces legal overhang and rebuilds investor confidence.
• A modest multiple expansion in the specialty chemicals space or positive commodity pricing moves that improve EBITDA.

Risks and counterarguments

These are the principal risks that justify a tight stop and modest position sizing:

• High leverage - Debt-to-equity is elevated at 2.86 and the company carries meaningful enterprise-level leverage. If earnings remain depressed, leverage multiplies downside and reduces optionality.
• Weather and seasonality - The Salt business is directly exposed to winter severity. Mild seasons materially compress revenue and margins.
• Operational noise and accounting/governance overhang - Recent derivative suits and prior accounting discussions create headline risk and could deter buyers until resolved.
• Valuation ambiguity - Trailing P/E is high (~50x) because earnings are depressed. If earnings stay weak, the market could mark down the stock further despite attractive EV/EBITDA.
• Commodity and input-cost risk - Costs for extraction, logistics, and chemicals can swing and compress margins.

Counterargument to the trade: The stock is not cheap on an earnings basis; trailing EPS is low and the P/E is ~50x. That suggests the market is pricing in either a permanent earnings decline or a need for capital allocation repairs. If the company cannot demonstrably reduce leverage or deliver consistent, positive operating cash flow, multiple compression and further downside are plausible. For patient, fundamentally oriented investors the better approach might be to wait for clear balance-sheet improvement or a meaningful cut to debt.

Conclusion and what would change my mind

Compass Minerals offers a tactical opportunity: EV/EBITDA around 7.25x, free cash flow of $77.9M and a market cap under $1B create a scenario where normalization of Salt demand and continued Plant Nutrition growth can produce 20%+ upside inside a 45-trading-day window. That said, leverage and governance/accounting noise are real risks and justify a tight stop at $19.00.

I would change my constructive view if any of the following occur: (a) net leverage increases materially or liquidity tightens, (b) another weak season in Salt is followed by guidance cuts or missed covenants, or (c) new accounting/governance developments exacerbate legal exposure. On the flip side, I would become more bullish if management delivers a clear deleveraging path, sequential margin improvement in Salt and Plant Nutrition, or a convincing remediation/update on governance issues.

Quick reference table

Key points

• Entry at $22.01 with a stop at $19.00 and primary target of $28.00; position-style trade with a 45-trading-day horizon.
• EV/EBITDA ~7.25x and free cash flow near $78M make a re-rating plausible if operations stabilize.
• Main risks are high leverage, weather sensitivity, and residual governance/accounting overhang.
• If the company deleverages or shows sustained margin improvement, the case for a larger, longer-term position strengthens.

Trade idea: tactical long at $22.01, stop $19.00, target $28.00, horizon position - mid term (45 trading days). Manage size given leverage and legal/operational risk.